Conclusion of non-exclusive discount contracts according to § 130a paragraph 8 of the German Civil Code V on drugs with the active substance bimatoprost (ATC code: S01EE03) within the period from 1.8.2021 to 31.7.2023 with the possibility of concluding a contract at any time (open-house model).

The AOK Rhineland-Palatinate/Saarland — The Health Fund offers discount contracts with the active substance bimatoprost (ATC code: S01EE03) to all interested pharmaceutical companies without a selection decision. Contracts are concluded within the framework of an “open house model”. The contracts offered are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Rhineland-Palatinate/Saarland — Die Gesundheitskasse. In the open house model, uniform conditions apply to all participants. Contract content, conditions and access procedures are uniform — individual negotiations are not conducted.

The contract terms are a maximum of 24 months, and the earliest start of the contract is August 1, 2021. All contracts end no later than 24 months after the date of the earliest start of the contract, regardless of the date of the respective contract conclusion. Joining or concluding a contract can be made at the first of each month within the 24-month period.

There is a right of termination 6 weeks at the end of each month in accordance with the provisions of the contract. Further information on the termination options can be found in the contract documents.

The AOK Rhineland-Palatinate / Saarland - The health insurance company reserves the right to replace the non-exclusive open house discount contracts with exclusive discount contracts as part of the Europe-wide tender process during the contract period. With the entry into force of exclusive discount contracts, the open house contracts are terminated in accordance with the contractual regulation, ie the open house contracts end automatically.

Interested pharmaceutical companies can request participation documents and contract documents from the contact address mentioned under I.1). Contracts for the active substance bimatoprost (ATC code: S01EE03) will be concluded for the first time with effect from 1.8.2021. Interested parties wishing to become a contractual partner on this date must submit the contract documents to AOK Rhineland-Palatinate/Saarland — Die Gesundheitskasse by 30.06.2021. It depends on access at AOK Rhineland-Palatinate/Saarland — Die Gesundheitskasse.

Note: The first award in this procedure will be awarded at the earliest 10 calendar days after this EU notice has been published in the Official Journal. Later contracts are possible during the 24-month maximum term on the first of each month. In the case of interested parties who would like to become a contractual partner on these subsequent dates, the receipt of the contract documents including Annex 1 must be submitted at the latest by the end of the month preceding the month before the desired start of the contract (e.g. receipt on April 30th when the contract starts on 1.6.). The exact deadlines for receipt will be announced with the contract documents. The present publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or the procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation "open procedure", are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to regulations under public procurement law, unless they are mandatory for legal reasons, is not associated with this.